In one patient with ERBB2 amplification detected in ctDNA following the development of resistance to platinum chemotherapy, treatment was changed to trastuzumab with reduced dose carboplatin and dose-dense paclitaxel, with significant tumour shrinkage and complete normalization of CA-125 achieved [224]. This evidence concerns the gene ERBB2 and neoplasm.